The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and olde ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Factors associated with higher odds of antiviral receipt include clinical influenza testing and ICU admission.

The Food and Drug Administration (FDA) has approved Steqeyma ® (ustekinumab-stba), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases in adults and ...

GSK has made the decision to withdraw Jesduvroq (daprodustat) from the US market. Approved in 2023, Jesduvroq, (HIF-PHI), is ...

Significant changes from previous guideline include recommendation that only FSH >25 IU required for POI diagnosis.

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of hepatotoxicity, following the Food and Drug Administration’s review of a ...

Black mothers are faced with a disproportionate number of barriers to breastfeeding compared to other racial and ethnic groups.

Black mothers are faced with a disproportionate number of barriers to breastfeeding compared to other racial and ethnic groups.

The newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions.